Skip to main content
OpenTrials
Completed

NCT Number: NCT06632067

Sugammadex and Time to Extubation in Ophthalmic Surgery

This study is to invastigate if patients treated with sugammadex compared to neostigmine/atropine would be extubate faster upon emergence of anesthesia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

General Anesthesia Using Endotracheal Intubation Extubation Readiness Neostigmine Ophthalmologic Surgical Procedure Sugammadex

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

China Medical University Hospital

Taichung, 404327, Taiwan

About this study

This is a retrospective case-control study including patients aged 18 years or older who underwent ophthalmic surgeries under general anesthesia with tracheal intubation between 2020 and 2022. Patients who received rocuronium as the sole neuromuscular blocking agent and were maintained with sevoflurane or desflurane and intravenous fentanyl were included. Based on the choice of reversal agent for neuromuscular blockade, patients were divided into two groups: the sugammadex group or the neostigmine group. Patients who underwent emergency surgery or combined surgeries with other specialties were excluded. Patient characteristics, including age, gender, ASA classification, weight, and height, were collected. Anesthesia-related medications were recorded. The time points of anesthesia induction, start and end of surgery, reversal agent administration, and tracheal extubation were documented.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

aged 18 years or older ophthalmic surgeries under general anesthesia with tracheal intubation between 2020 and 2022 received rocuronium as the sole neuromuscular blocking agent maintained with sevoflurane or desflurane and intravenous fentanyl

Exclusion criteria

emergency surgery combined surgeries with other specialties

Treatment and study plan

Sugammadex

Drug

sugammadex used for neuromuscular reversal

Neostigmine + Atropine

Drug

Neostigmine and Atropine used for neuromuscular reversal

Primary outcomes

  1. Time From reversal to extubation

    Time frame: Time From reversal to extubation

    Time From reversal to extubation

  2. Time From the end of surgery to reversal

    Time frame: Time From the end of surgery to reversal

    Time From the end of surgery to reversal

Secondary outcomes

  1. Time From induction to the end of surgery

    Time frame: Time From induction to the end of surgery

    Time From induction to the end of surgery

Sponsors and collaborators

Lead sponsor

China Medical University Hospital

Other

Registry information

Official study title

Comparison of Sugammadex and Neostigmine for Time to Extubation in Adult Patients Undergoing Routine Ophthalmic Surgery Under General Anesthesia

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Oct 8, 2024
Registry last updated
Oct 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.